The American side is asking to speed up the process of developing COVID-19 therapeutics. 
The ACTIV-3/INSIGHT 014 protocol entitled “Multicenter, adaptive, Randomized, Blind Controlled trial of the safety and efficacy of investigational therapy for hospitalized COVID-19 patients” has been submitted for regulatory approval in Georgia. An urgent randomized controlled trial aims to evaluate the safety and efficacy of monoclonal antibodies to SARS-CoV-2 and other COVID-19 therapeutics.

Monoclonal antibodies are among a number of highly prioritized therapeutics being evaluated for the treatment of COVID-19